ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report)’s stock price was down 3.8% during trading on Monday . The company traded as low as C$5.98 and last traded at C$6.00. Approximately 19,701 shares traded hands during mid-day trading, an increase of 492% from the average daily volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Stock Performance
The company has a debt-to-equity ratio of 108.33, a current ratio of 0.51 and a quick ratio of 1.30. The company has a fifty day moving average price of C$6.00. The firm has a market cap of C$51.48 million, a PE ratio of -1.78 and a beta of 1.19.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Stories
- Five stocks we like better than ProMIS Neurosciences
- What is the Hang Seng index?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Applied Materials Market Capitulates: Now is the Time to Buy
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
